已收盘 02-06 16:00:00 美东时间
+0.230
+1.07%
今日重点评级关注:富国银行:维持Milestone Pharmaceuticals"超配"评级,目标价从4美元升至8美元;富国银行:维持Kyverna Therapeutics"超配"评级,目标价从31美元升至33美元
2025-12-17 10:46
高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价;Adient、DoorDash、多邻国、Figma、飞塔信息、HubSpot、康丽数码等遭大行下调目标价
2025-11-07 10:14
Cantor Fitzgerald analyst Steve Seedhouse maintains Innoviva (NASDAQ:INVA) with a Overweight and raises the price target from $29 to $31.
2025-11-06 22:42
Innoviva (NASDAQ:INVA) reported quarterly earnings of $1.08 per share which beat the analyst consensus estimate of $0.52 by 109.71 percent. This is a 5300 percent increase over earnings of $0.02 per share from the same
2025-11-06 05:47
今日重点评级关注:Maxim Group:上调Adial Pharmaceuticals评级至"买入",目标价1.5美元;BTIG:维持Climb Bio"买入"评级,目标价从7美元升至8美元
2025-10-01 20:13
Goldman Sachs analyst Asad Haider initiates coverage on Innoviva (NASDAQ:INVA) with a Sell rating and announces Price Target of $17.
2025-09-30 21:06
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Innoviva (NASDAQ:INVA) with a Buy and raises the price target from $40 to $45.
2025-08-11 18:41